Haemodynamics, fluids & transfusion
The role of fibrinogen concentrate in the reduction of allogeneic blood product requirements: a systematic review and meta-analysis
Pooled result · Red blood cell units (adults)Result — go to the resultIncidence rate ratio 0.72 95% CI 0.59–0.89Authors' conclusion
This meta-analysis suggests FC administered for acquired hypofibrinogenaemia can reduce blood product transfusions in adults, with no obvious safety concerns, compared with other treatments.
Study context
- Population
- Patients from a range of clinical settings who received fibrinogen concentrate (FC) for acquired hypofibrinogenaemiapatients in 58 studies
- Participants
- 13,530 patients
- Comparison
- Difference in outcome between FC and all other treatments
- Outcome
- Red blood cell units (adults)
Methodological detailsseparate analyses for adult and paediatric patients
- Separate analyses for adult and paediatric patients
Pooled result
As reported in the abstract
Incidence rate ratio
0.72
95% CI 0.59–0.89
P = 0.002
FC vs Other treatments
IRR 0.72 (95% CI 0.59–0.89); P = 0.002
Further pooled results
| Outcome | IRR (95% CI) | P value | |
|---|---|---|---|
| Fresh frozen plasma units (adults)31% fewer with FC | 0.69 (0.54–0.89) | P = 0.004 | |
| Platelet units (adults)44% less with FC | 0.56 (0.33–0.95) | P = 0.03 | |
| 0.20.5125Incidence rate ratio (log scale) |
- Platelet units (adults): These results were largely driven by cardiac surgery studies.
Mortality (adults)
- No significant difference between treatments
Paediatric patients, all outcomes analysed
- No significant difference between treatments
Use and quantity of blood products (RCT subanalysis)
- Significantly reduced with FC
Original publication
The role of fibrinogen concentrate in the reduction of allogeneic blood product requirements: a systematic review and meta-analysis. Br J Anaesth. Published 12 October 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →